Právní předpis byl sestaven k datu 06.03.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx věcí,
kterým xx mění a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. října 2023 bylo generální xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxx zakázaných látek x metod xxxxxxx xxx rok 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx ve xxxxxx.
X xxxxx xxxxxx Přílohy X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x souladu x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx dne 18. xxxxxx 2024 x xxxxxxxxx Přílohu X xxx rok 2023, platnou xx 1. ledna 2023, xxxxx vstoupila v xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 a xxxx vyhlášena xxx č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 x xxxx xxxxxxx xx českého xxxxxx xx vyhlašují xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. XXXx. Xxxxxx, Ph.D., XX.X., x. x.
xxxxxx xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard v xxxxx Xxxxxxxxx antidopingového xxxxxxxx.
Xxxxxx xx každoročně xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx agenturou (XXXX). Seznam je xxxxxx od 1. xxxxx 2024.
Xxxxxxxxx xxxx Xxxxxxx zakázaných látek x xxxxx bude xxxxxxxxx XXXX x xxxx xxxxxxxxxx v xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx soutěži
Pokud XXXX xxx xxxx xxxxx neschválila xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx xxxxxxxxx, xx do xxxxx Xxxxxxx a procesu xxxxxx Vzorku.
Zakázané xxxxx
Xx xxxxxxx, xx daná xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx článku 4.2.2 Světového antidopingového Xxxxxx „xxx účely xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Specifickými xxxxxxx, x xxxxxxxx těch xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx dopingu. Žádná Xxxxxxxx metoda nebude Xxxxxxxxxxx xxxxxxx, pokud xxxx x Seznamu xxxxxxxxx označena jako Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx neměly xxx xxxxxx způsobem xxxxxxxxxx xx méně xxxxxxxx xxxx méně nebezpečné xxx xxxx dopingové xxxxx nebo metody. Xxx spíše x xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x jinému xxxxx xxx ke zlepšení xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx xxxx látky, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx látky xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není v xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární použití), xx xxxxxxxx xxxxx.
Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).
X1 XXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxxxx látky.
Anabolické xxxxx jsou zakázány.
S1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)
Xxx xxxxxxxxx podání, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on) |
• |
testosteron |
|
|
• |
epi-dihydrotestosteron (17β-hydroxy-5β-androstan-3-on) |
• |
tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-norpregna-4-en-17α-ol) |
• |
trenbolon (17β-hydroxyestr-4,9,11-trien-3-on) |
|
|
• |
fluoxymesteron |
• |
trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 a XX-11], xxxxxxx x xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X MIMETIKA
ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx xxxxx x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (EPO) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx EPO, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky x xxxxxx xxxxxxxxxx, např. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (BAY 85-3934); roxadustat (FG-4592); xxxxxxxxxx (AKB-6548); xenon.
S2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Agonisté xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX
X2.2.1 Xxxxxxx stimulující xxxxxxxxxxx x xxxx, mimo xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (XX),
• xxxxxxxxxxxx xxxxxx (XX),
• hormon xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) a jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x triptorelin),
• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx hormon (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx včetně:
• analogy xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, somapacitan a xxxxxxxxxx,
• xxxxxxxxx růstového xxxxxxx, xxxx. AOD-9604 x hGH 176–191.
X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, mimo jiné xxxxxx:
• xxxxxx xxxxxxxxxx xxxxxxx hormon (GHRH) x xxxx analogy, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx růstového hormonu (XXX) a xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, lenomorelin (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx uvolňující GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].
X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX
Xxxx xxxx včetně:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)
• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx analogy
• xxxxxxxxxx xxxxxxx faktory (XXX)
• růstový xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)
• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)
x xxxxx růstové faktory xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx selektivní x xxxxxxxxxxxx beta-2 xxxxxxxx včetně xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx dávce;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 hodin;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxx vyšším než 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky a xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Sportovec xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, že xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx xxxx xxxxxxx maximální dávky.
S4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxxx látky xx xxxxxxx X4.1 a X4.2 xxxx Specifické xxxxx.
Xxxxx xxxxxxxx do xxxx X4.3 x X4.4 xxxx Nespecifické xxxxx.
Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. INHIBITORY XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan) |
|
|
• |
3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
|
• |
konkurenty xxxxxxxxx xxxxxxxx IIB, xxxx.: |
- xxxxx xxxxxxxxx nebo xxxxxx expresi xxxxxxxxxx |
||
|
- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (např. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (např. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, xxxxxxxx peroxizomovými xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (GW1516, XX501516) x agonisté Xxx-xxxɑ , xxxx. XX9009, XX9011
X4.4.2 xxxxxxxx a xxxxxxxx insulinů
S4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX A XXXXXXXXX LÁTKY
ZAKÁZANÉ XXXXX (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxx zakázané xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Xxxxxxxxx, xxxx xxxx.:
xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. konivaptan, mozavaptan, xxxxxxxxx;
• Xxxxxxxxxxx expandéry xxxxxxxx intravenózně, xxxx.:
xxxxxxx, xxxxxxx, hydroxyetyl škrob, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx podání xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx prahovým xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx ve xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (AAF), xxxxx Sportovec xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) na tuto xxxxx xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx nebo jinou xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx jsou Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx produktů z xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx do oběhového xxxxxxx x výjimkou xxxxxxxx xxxxxx xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x registrovaném xxxxxxxxx xxxxxx.
X1.2. Umělé zvyšování xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, např. xxxxxx náhražky xx xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ A XXXXXXXXX XXXXXXXXXX
Xxxxxxxx je xxxxxxxxxxx:
X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.
Xxxx jiné xxxxxx:
Xxxxxx x/xxxx úprava Xxxxxx, např. přidáním xxxxxxx ke Vzorku.
M2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více než xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx v průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. XXXXXX X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, umlčování xxxx x xxxxxxxxxxx xxxxxxx xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx geneticky xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxx látky x výjimkou xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx sekci: kokain x metylendioxymetamfetamin (MDMA/„extáze“)
Všechna xxxxxxxxxxx, včetně xxxxx xxxxxxxxx izomerů, např. x- a x-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx včetně:
|
• |
2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin) |
• |
fenbutrazát |
• |
oxilofrin (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x xxxxx xxxxx x podobnou chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx kožního, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x stimulancia zařazená xx Monitorovacího xxxxxxxx 20245).
X7 NARKOTIKA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: diamorfin (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx v této xxxxx xxxx Specifické xxxxx. Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (THC)
Všechny xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, xxxx.
• x konopí (hašiš, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx
• xxxxxxxx a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)
• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• kanabidiol
S9 XXXXXXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.
Všechny xxxxxxxxxxxxxxx xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx xxxxxx (včetně xxxxxxxxxxx x topického: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx výrobcem xxxxxxxxxxxx dávek a xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X URČITÝCH SPORTECH
Všechny xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky xx xxxxxx, xxxxxxxxxxx skoky / U-rampa a xxxxxxxxx U-rampa / xxx xxx
• xxxxxxxxxxxx xxxxx (XXX)
• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx x xxxxxxx na xxxx
• xxxxxxxx (xxxxxxx disciplíny) (XXXX)
• šipky (XXX)
• xxxx (IGF)
• xxxxxxxx (XXX)
• střelba (XXXX, XXX)*
* xxxxxxxx xxxx Xxxx soutěž
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Znění xxxxxxxxxxx xxxxxxx v xxxxxxxxx xxxxxx
&xxxx;
1) katin (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx x moči xxxxx xxx 5 mikrogramů x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx xxx 150 mikrogramů v 1 xx.
3) efedrin x xxxxxxxxxxxx: xxxxxxxx xxx koncentraci v xxxx vyšší xxx 10 xxxxxxxxxx x 1 xx.
4) xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx podávání, např. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.
5) bupropion, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.
Informace
Právní xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx dnem 28.1.2024.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, pokud se xxxx netýká derogační xxxxx shora uvedeného xxxxxxxx xxxxxxxx